Update on leukotriene receptor antagonists in preschool children wheezing disorders

Italian Journal of Pediatrics

Francesca Santamaria¹  Angela Di Giorgio¹  Angelo Manna¹  Sara De Stefano¹  Marco Maglione¹  Silvia Montella¹ 

[1] Department of Pediatrics, Federico II University, Via Sergio Pansini, 5, Naples, 80131, Italy

关键词: Bronchiolitis;    Wheezing;    Preschool children;    Asthma;    Leukotriene receptor antagonists;   

Others  :  825875
DOI  :  10.1186/1824-7288-38-29

 received in 2012-02-13, accepted in 2012-06-04,  发布年份 2012

【 摘 要 】

Asthma is the most common chronic disease in young children. About 40% of all preschool children regularly wheeze during common cold infections. The heterogeneity of wheezing phenotypes early in life and various anatomical and emotional factors unique to young children present significant challenges in the clinical management of this problem. Anti-inflammatory therapy, mainly consisting of inhaled corticosteroids (ICS), is the cornerstone of asthma management. Since Leukotrienes (LTs) are chemical mediators of airway inflammation in asthma, the leukotriene receptor antagonists (LTRAs) are traditionally used as potent anti-inflammatory drugs in the long-term treatment of asthma in adults, adolescents, and school-age children. In particular, montelukast decreases airway inflammation, and has also a bronchoprotective effect. The main guidelines on asthma management have confirmed the clinical utility of LTRAs in children older than five years. In the present review we describe the most recent advances on the use of LTRAs in the treatment of preschool wheezing disorders. LTRAs are effective in young children with virus-induced wheeze and with multiple-trigger disease. Conflicting data do not allow to reach definitive conclusions on LTRAs efficacy in bronchiolitis or post-bronchiolitis wheeze, and in acute asthma. The excellent safety profile of montelukast and the possibility of oral administration, that entails better compliance from young children, represent the main strengths of its use in preschool children. Montelukast is a valid alternative to ICS especially in poorly compliant preschool children, or in subjects who show adverse effects related to long-term steroid therapy.

【 授权许可】

   
2012 Montella et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ: Asthma and wheezing in the first six years of life. N Engl J Med 1995, 332:133-138.
• [2]Stevens CA, Turner D, Kuehni CE, Couriel JM, Silverman M: The economic impact of preschool asthma and wheeze. Eur Respir J 2003, 21:1000-1006.
• [3]Zielen S, Rose MA, Bez C, Jarisch A, Reichenbach J, Hofmann D: Effectiveness of budesonide nebulising suspension compared to disodium cromoglycate in early childhood asthma. Curr Med Res Opin 2006, 22:367-373.
• [4]de Blic J, Delacourt C, Le Bourgeois M, Mahut B, Ostinelli J, Caswell C, Scheinmann P: Efficacy of nebulized budesonide in treatment of severe infantile asthma: a double-blind study. J Allergy Clin Immunol 1996, 98:14-20.
• [5]Ilangovan P, Pedersen S, Godfrey S, Nikander K, Noviski N, Warner JO: Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension. Arch Dis Child 1993, 68:356-359.
• [6]Papi A, Nicolini G, Boner AL, Baraldi E, Cutrera R, Fabbri LM, Rossi GA: Short term efficacy of nebulized beclomethasone in mild-to-moderate wheezing episodes in pre-school children. Ital J Pediatr 2011, 37:39. BioMed Central Full Text
• [7]Zeiger RS, Mauger D, Bacharier LB, Guilbert TW, Martinez FD, Lemanske RF Jr, Strunk RC, Covar R, Szefler SJ, Boehmer S, Jackson DJ, Sorkness CA, Gern JE, Kelly HW, Friedman NJ, Mellon MH, Schatz M, Morgan WJ, Chinchilli VM, Raissy HH, Bade E, Malka-Rais J, Beigelman A, Taussig LM, CARE Network of the National Heart, Lung, and Blood Institute: Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med 2011, 365:1990-2001.
• [8]Baraldi E, Rossi GA, Boner AL: Beclomethasone and Salbutamol Treatment (BEST) for Children Study Group (NCT00497523). Budesonide in preschool-age children with recurrent wheezing. N Engl J Med 2012, 366:570-571.
• [9]Ducharme FM, Zemek RL, Schuh S: Oral corticosteroids in children with wheezing. N Engl J Med 2009, 360:1674.
• [10]Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F: Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 2006, 354:1998-2005.
• [11]Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, Bacharier LB, Lemanske RF Jr, Strunk RC, Allen DB, Bloomberg GR, Heldt G, Krawiec M, Larsen G, Liu AH, Chinchilli VM, Sorkness CA, Taussig LM, Martinez FD: Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006, 354:1985-1997.
• [12]Murray CS, Woodcock A, Langley SJ, Morris J, Custovic A, IFWIN study team: Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet 2006, 368:754-762.
• [13]Bacharier LB, Boner A, Carlsen KH, Eigenmann PA, Frischer T, Götz M, Helms PJ, Hunt J, Liu A, Papadopoulos N, Platts-Mills T, Pohunek P, Simons FE, Valovirta E, Wahn U, Wildhaber J, European Pediatric Asthma Group: Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy 2008, 63:5-34.
• [14]Amirav I: Aerosol Therapy. Ital J Pediatr 2004, 30:147-156.
• [15]GINA Report, Global Strategy for Asthma Management and Prevention. http://www.ginasthma.com webcite. Last access on: 09 February 2012
• [16]British Thoracic Society, Scottish Intercollegiate Guidelines Network: British Guideline on the management of asthma. http://www.brit-thoracic.org.uk webcite. Last access on: 09
• [17]National Heart, Lung, and Blood Institute National Asthma Education and Prevention Program: Expert Panel Report 3. Guidelines for the Diagnosis and Management of Asthma. http://www.nhlbi.nih.gov webcite. Last access on: 09 February 2012
• [18]Arm JP, Lee TH: Chemical mediators: Leukotrienes and eicosanoids. In Bronchial asthma: mechanisms and therapeutics. Edited by Weiss EB, Stein M. Boston: Little Brown; 1993:112-134.
• [19]Lewis RA, Austen KF, Soberman RJ: Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990, 323:645-655.
• [20]Arm JP, Lee TH: Sulphidopeptide leukotrienes in asthma. Clin Sci 1993, 84:501-510.
• [21]Bernstein PR: Chemistry and structure activity relationships of leukotriene receptor antagonists. Am J Respir Crit Care Med 1998, 157:s220-s226.
• [22]Hakim F, Vilzoni D, Adler A, Livnat G, Tal A, Bentur L: The effect of montelukast on bronchial hyperreactivity in preschool children. Chest 2007, 13:180-186.
• [23]de Benedictis FM, del Giudice MM, Forenza N, Decimo F, de Benedictis D, Capristo A: Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children. Eur Respir J 2006, 28:291-295.
• [24]Bisgaard H: Role of leukotrienes in asthma pathophysiology. Pediatr Pulmonol 2000, 30:166-176.
• [25]Corradi M, Zinelli C, Caffarelli C: Exhaled breath biomarkers in asthmatic children. Inflamm Allergy Drug Targets 2007, 6:150-159.
• [26]Csoma Z, Kharitonov SA, Balint B, Bush A, Wilson NM, Barnes PJ: Increased leukotrienes in exhaled breath condensate in childhood asthma. Am J Respir Crit Care Med 2002, 166:1345-1349.
• [27]Walia M, Lodha R, Kabra SK: Montelukast in pediatric asthma management. Indian J Pediatr 2006, 73:275-282.
• [28]Amlani S, Nadarajah T, McIvor RA: Montelukast for the treatment of asthma in the adult population. Expert Opin Pharmacother 2011, 12:2119-2128.
• [29]Cheng H, Leff JA, Amin R, Gertz BJ, De Smet M, Noonan N, Rogers JD, Malbecq W, Meisner D, Somers G: Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res 1996, 13:445-448.
• [30]Bisgaard H, Nielsen KG: Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool children. Am J Respir Crit Care Med 2000, 162:187-190.
• [31]Straub DA, Minocchieri S, Moeller A, Hamacher J, Wildhaber JH: The effect of montelukast on exhaled nitric oxide and lung function in asthmatic children 2 to 5 years old. Chest 2005, 127:509-514.
• [32]Straub DA, Moeller A, Minocchieri S, Hamacher J, Sennhauser FH, Hall GL, Wildhaber JH: The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma. Eur Respir J 2005, 25:289-294.
• [33]Robertson CF, Price D, Henry R, Mellis C, Glasgow N, Fitzgerald D, Lee AJ, Turner J, Sant M: Short-course montelukast for intermittent asthma in children: a randomised controlled trial. Am J Respir Crit Care Med 2007, 175:323-329.
• [34]Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, Michele TM, Reiss TF, Nguyen HH, Bratton DL: Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001, 108:E48.
• [35]Davies GM, Dasbach EJ, Santanello NC, Knorr BA, Bratton DL: The effect of montelukast versus usual care on health care resource utilization in children aged 2 to 5 years with asthma. Clin Ther 2004, 26:1895-1904.
• [36]Bisgaard H, Zielen S, Garcia-Garcia ML, Johnston SL, Gilles L, Menten J, Tozzi CA, Polos P: Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005, 171:315-322.
• [37]Weinberger M: Montelukast for viral respiratory infection-induced exacerbations of asthma. Am J Respir Crit Care Med 2005, 172:783.
• [38]Szefler SJ, Baker JW, Uryniak T, Goldman M, Silkoff PE: Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. J Allergy Clin Immunol 2007, 120:1043-1049.
• [39]Kooi EM, Schokker S, Marike Boezen H, de Vries TW, Vaessen-Verberne AA, van der Molen T, Duiverman EJ: Fluticasone or montelukast for preschool children with asthma-like symptoms: Randomized controlled trial. Pulm Pharmacol Ther 2008, 21:798-804.
• [40]Bacharier LB, Phillips BR, Zeiger RS, Szefler SJ, Martinez FD, Lemanske RF Jr, Sorkness CA, Bloomberg GR, Morgan WJ, Paul IM, Guilbert T, Krawiec M, Covar R, Larsen G, Mellon M, Moss MH, Chinchilli VM, Taussig LM, Strunk RC, CARE Network: Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol 2008, 122:1127-1135.
• [41]Allen-Ramey FC, Markson LE, Riedel AA, Sajjan S, Weiss KB: Patterns of asthma-related health care resource use in children treated with montelukast or fluticasone. Curr Med Res Opin 2006, 22:1453-1461.
• [42]Smyth AR, Barbato A, Beydon N, Bisgaard H, de Boeck K, Brand P, Bush A, Fauroux B, de Jongste J, Korppi M, O’Callaghan C, Pijnenburg M, Ratjen F, Southern K, Spencer D, Thomson A, Vyas H, Warris A, Merkus PJ: Respiratory medicines for children: current evidence, unlicensed use and research priorities. Eur Respir J 2010, 35:247-265.
• [43]Bush A: Practice imperfect–treatment for wheezing in preschoolers. N Engl J Med 2009, 360:409-410.
• [44]Johnston NW, Mandhane PJ, Dai J, Duncan JM, Greene JM, Lambert K, Sears MR: Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics 2007, 120:e702-e712.
• [45]Lenney W, Boner AL, Bont L, Bush A, Carlsen KH, Eber E, Fauroux B, Götz M, Greenough A, Grigg J, Hull J, Kimpen J, Sánchez Luna M, de Benedictis FM: Medicines used in respiratory diseases only seen in children. Eur Respir J 2009, 34:531-551.
• [46]Da Dalt L, Callegaro S, Carraro S, Andreola B, Corradi M, Baraldi E: Nasal lavage leukotrienes in infants with RSV bronchiolitis. Pediatr Allergy Immunol 2007, 18:100-104.
• [47]Amirav I, Luder AS, Kruger N, Borovitch Y, Babai I, Miron D, Zuker M, Tal G, Mandelberg A: A double-blind, placebocontrolled, randomized trial of montelukast for acute bronchiolitis. Pediatrics 2008, 122:e1249-e1255.
• [48]Bisgaard H, Flores-Nunez A, Goh A, Azimi P, Halkas A, Malice MP, Marchal JL, Dass SB, Reiss TF, Knorr BA: Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med 2008, 178:854-860.
• [49]Proesmans M, Sauer K, Govaere E, Raes M, De Bilderling G, De Boeck K: Montelukast does not prevent reactive airway disease in young children hospitalized for RSV bronchiolitis. Acta Paediatr 2009, 98:1830-1834.
• [50]Bisgaard H: A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med 2003, 167:379-383.
• [51]Kim CK, Choi J, Kim HB, Callaway Z, Shin BM, Kim JT, Fujisawa T, Koh YYA: Randomized intervention of montelukast for post-bronchiolitis: effect on eosinophil degranulation. J Pediatr 2010, 156:749-754.
• [52]Harmanci K, Bakirtas A, Turktas I, Degim T: Oral montelukast treatment of preschool-aged children with acute asthma. Ann Allergy Asthma Immunol 2006, 96:731-735.
• [53]Kozer E, Lotem Z, Elgarushe M, Torgovicky R, Cohen R, Cohen HA, Berkovitch M: RCT of montelukast as prophylaxis for upper respiratory tract infections in children. Pediatrics 2012, 129:285-290.
• [54]Bisgaard H, Skoner D, Boza ML, Tozzi CA, Newcomb K, Reiss TF, Knorr B, Noonan G: Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol 2009, 44:568-579.
• [55]Baiardi P, Ceci A, Felisi M, Cantarutti L, Girotto S, Sturkenboom M, Baraldi E: In-label and off-label use of respiratory drugs in the Italian paediatric population. Acta Paediatr 2010, 99:544-549.
• [56]Forrester MB: Pediatric montelukast ingestions reported to Texas poison control centers, 2000–2005. J Toxicol Environ Health A 2007, 70:1792-1797.
• [57]Cobb DB, Abbott CL, Watson WA, Fernández MC: High-dose montelukast exposures in a 3-year-old and a 5-year-old child. Vet Hum Toxicol 2002, 44:91-92.
• [58]Churg J, Strauss L: Allergic granulomatosis, allergic angitis, and periarteritis nodosa. Am J Pathol 1951, 27:277-301.
• [59]Nathani N, Little MA, Kunst H, Wilson D, Thickett DR: Churg–Strauss syndrome and leukotriene antagonist use: a respiratory perspective. Thorax 2008, 63:883-888.
• [60]Philip G, Hustad C, Noonan G, Malice MP, Ezekowitz A, Reiss TF, Knorr B: Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 2009, 124:691-696.
• [61]Simons FE, Villa JR, Lee BW, Teper AM, Lyttle B, Aristizabal G, Laessig W, Schuster A, Perez-Frias J, Sekerel BE, Menten J, Leff JA: Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr 2001, 138:694-698.
• [62]Brand PL, Baraldi E, Bisgaard H, Boner AL, Castro-Rodriguez JA, Custovic A, de Blic J, de Jongste JC, Eber E, Everard ML, Frey U, Gappa M, Garcia-Marcos L, Grigg J, Lenney W, Le Souëf P, McKenzie S, Merkus PJ, Midulla F, Paton JY, Piacentini G, Pohunek P, Rossi GA, Seddon P, Silverman M, Sly PD, Stick S, Valiulis A, van Aalderen WM, Wildhaber JH, et al.: Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur Respir J 2008, 32:1096-1110.
• [63]Schultz A, Payne D: Danger of using an unreliable classification system for preschool wheeze. Eur Respir J 2009, 33:944-945.
• [64]Schultz A, Devadason SG, Savenije OE, Sly PD, Le Souëf PN, Brand PL: The transient value of classifying preschool wheeze into episodic viral wheeze and multiple trigger wheeze. Acta Paediatr 2010, 99:56-60.
• [65]Baraldi E, Donegà S, Carraro S, Farina M, Barbato A, Cutrone C: Tracheobronchomalacia in wheezing young children poorly responsive to asthma therapy. Allergy 2010, 65:1064-1065.
• [66]Bacharier LB: Viral-induced wheezing episodes in preschool children: approaches to therapy. Curr Opin Pulm Med 2010, 16:31-35.
• [67]Philip G, Pedinoff A, Vandormael K, Tymofyeyev Y, Smugar SS, Reiss TF, Korenblat PE: A phase I randomized, placebo-controlled, dose-exploration study of single-dose inhaled montelukast in patients with chronic asthma. J Asthma 2010, 47:1078-1084.